2016 Archived Content
Wednesday, February 10, 6:00-9:00 pm
(SC1) Short Course: Introduction to High-Content Phenotypic Screening
The ever-increasing demand for improved productivity in research through the generation of robust analysis outputs has driven both the development and deployment of automated high-content analysis (HCA) and phenotypic cell-based approaches to drug discovery. In contrast to the more traditional cellular analysis and target-based approaches, here the researcher is able to evaluate the efficacy of potential therapeutics by monitoring the physiological state of cells through the simultaneous analysis of multiple cellular parameters in the context of an intact biological system. This course will cover the key features of HCS/A technologies and the best approaches to using these technologies for phenotypic cell-based screening.
Instructor: Anthony M. Davies, Ph.D., Center Director, Translational Cell Imaging Queensland (TCIQ), Institute of Health Biomedical Innovation, Queensland University of Technology
Who should attend?
This course has been developed to introduce and facilitate scientists who are either moving into the field or who are interested in further developing new phenotypic discovery applications and tools for use with these technologies.
(i) An introduction to HCA technologies
(ii) Advanced cell-based models for use with HCA
(iii) Worked examples of the phenotypic screening approach and future directions
(iv) Group discussion and Q&A
- Develop a familiarity of the basics of HCS/A technologies
- Gain an understanding of the capabilities of this technology
- Learn of the latest developments in cell-based models for use in this field
- Get a better understanding of the key principles of assay design and development for phenotypic screening
Thursday, February 11, 6:30-9:00 pm
(SC2) Expert ThinkTank: How to Meet the Need for Physiologically Relevant Assays
It used to be adequate to build target-specific and robust assays to drive lead optimization. These assays were relatively inexpensive and reliable and could be counted on to provide chemists with usable results. However, with time, it has become apparent that it is not enough to be robust and target specific. To build therapies for patients, we need to have assays that are more predictive of patient outcome. The current buzz words are "physiologically relevant assays." This session will explore the need for physiologically relevant assays and explore the ways that we can achieve this endpoint.
Discussion topics include:
What is the driver for more physiologically relevant assays?
What is the current state of the art?
Advantages and shortcomings of the current technologies
What is needed to build more physiologically relevant assays?
What are the requirements for cells, assay systems and budget?
What are the compromises that can be allowed when building tools?
What would be the ideal outcome and timelines?
Lisa Minor, Ph.D., President, In Vitro Strategies, LLC
Anthony M. Davies, Ph.D., Center Director, Translational Cell Imaging Queensland (TCIQ), Institute of Health Biomedical Innovation, Queensland University of Technology
Regis Doyonnas, Ph.D., Senior Principal Scientist, High-Content Screening and HTS-Flow Cytometry, Primary Pharmacology Group, Pfizer
Susanne Heynen-Genel, Ph.D., Director, High-Content Screening Systems, Sanford Burnham Prebys Medical Discovery Institute
Charles C. Hong, M.D., Ph.D., Associate Professor, Cardiovascular Medicine, Pharmacology, and Cell & Developmental Biology, Vanderbilt University School of Medicine
Fred King, Ph.D., Research Investigator, Novartis Institute for BioMedical Research
Tae-Wan Kim, Ph.D., Associate Professor, Department of Pathology & Cell Biology, Columbia University Medical Center
Madhu Lal-Nag, Ph.D., Acting Team Lead, RNAi Screening Facility, National Center for Advancing Translational Sciences, National Institutes of Health
Ming Lei, Senior Scientist, Lead Discovery & Optimization, Bristol-Myers Squibb
Zhuyin Li, Ph.D., Translational Biomarker Team Lead, Lead Discovery & Optimization, Bristol-Myers Squibb